Conclusions In this study, the authors showed that the lower the visual-field defect, the lower was LF, except at stage 5 of GSS2. As testeretest changes exceeding LF could represent a sign of progression, the authors suggest that clinicians using this classification system calculate LF, in order to better differentiate true progression from variability.
INTRODUCTION
The analysis of changes in standard automated perimetry (SAP) over time is a key element for detecting glaucoma progression. Four main approaches to evaluate perimetric progression are available: clinical judgement of a series of tests, classification systems, event analysis and trend analysis. All these approaches are limited by the 'noise' of variability, which is the result of changes in the nature of the visual system, the testing situation, the features of the perimetric program and the condition of the patient. 1 In a regression model of any perimetric parameter over time, the regression line represents the expected change, whereas long-term fluctuation (LF) is an area of uncertainty both below (apparent worsening) and above (apparent improvement) this line. In clinical practice, an improvement in results due to LF has limited relevance (this is clearly an artefact because glaucoma cannot improve by definition), whereas a worsening of results due to fluctuation is extremely important because LF can mask progression or even mimic glaucomatous deterioration. 1 Several mathematical models have been proposed for measuring LF 1e3 ; studies of normal subjects, suspected glaucoma and glaucoma patients have also shown that LF is predictable on the basis of mean deviation (MD). Among the strategies used to evaluate the amount of visual-field defect and its changes over time, the Glaucoma Staging System (GSS) is gaining popularity due to its simplicity of use. By plotting MD against the pattern standard deviation (PSD) or the corrected PSD (CPSD), GSS classifies visual-field results into six stages (from 0 to 5) and three types of defects (localised, mixed, generalised). 7 Recently, the system has been implemented (GSS2) by introducing a borderline stage between stages 0 and 1. 8 Although GSS2 may be useful in evaluating glaucoma changes at follow-up, 9 currently there are no studies measuring LF at different stages of GSS2, which is the aim of this multicentre study.
MATERIALS AND METHODS
This retrospective study involved seven University Eye Clinics: Genoa, Milan (San Paolo Hospital), Parma, Pisa, Rome (GB Bietti Foundation), Siena (Italy) and Zaragoza (Spain). It was in adherence to the tenets of the Declaration of Helsinki; patients were informed about the study and gave informed consent for data treatment.
Patient selection
This study included patients with ocular hypertension (OH) or primary open-angle glaucoma (POAG), pseudoexfoliative glaucoma (PEG) or pigmentary glaucoma (PG) who fulfilled inclusion and exclusion criteria. Each of the seven centres recruited 25 cases. One eye per subject was randomly selected if both eyes met the inclusion criteria.
The inclusion criteria were: 18 years of age or older; patients with OH, POAG, PEG and PG; stability of the disease during the study period (see below for definition); visual fields performed using the Humphrey Field Analyser (HFA) II 750 (Zeiss Humphrey Systems, Dublin, California) 24-2 or 30-2 test with Standard Swedish Interactive Threshold Algorithm (SITA) strategy; presence of at least four reliable tests (<25% false-positive responses, <25% false-negative responses and <25% fixation losses) over a 2-year period. The exclusion criteria were: normal tension glaucoma; secondary glaucomas; the development of cataract or any pathology affecting visual acuity and visual field at any time during the study period; any change in the program used to test the patient at follow-up; learning effect at visual field during the study period; neurological disorders; systemic and ophthalmic disorders affecting SAP results or reliability. Diagnosis was based on a chart review of medical history, biomicroscopy, gonioscopy, Goldmann applanation tonometry and indirect fundus ophthalmoscopy.
POAG eyes were defined as having an intraocular pressure (IOP) higher than 21 mm Hg prior medication, glaucomatous optic neuropathy (diffuse neuroretinal rim narrowing with concentric enlargement of the optic cup, localised notching, or both) 10 and repeatable abnormal results at SAP. OH were defined as having an IOP>21 mmHg without medication, no ocular pathologies and normal optic nerve head appearance and visual-field results.
Stability of the disease
To be included, patients had to have no changes in mean IOP, medical regimen, optic nerve head appearance at ophthalmoscopy and SAP for the duration of the study. IOP was arbitrarily considered stable if changes of less than 20% in mean value (obtained from office-hour curves, ie, four measurements between 08:00 and 16:00) occurred compared with the first visit.
A battery of visual fields was considered stable if the first and last tests showed absence of: (1) the development of a new scotoma (defined as three or more contiguous points with p<5%, or two or more contiguous points with p<1%); (2) the expansion of an existing scotoma into previously normal regions (defined as three or more contiguous points with p<5%, or two or more contiguous points with p<1%); (3) the deepening of an existing scotoma (defined as a decrease in the probability value or a reduction in sensitivity of at least 5 dB in three or more contiguous points, or 10 dB or more in at least two contiguous points 11 ); and (4) a worsening probability value for any perimetric index. Any change occurring in the second and third test was considered as variability. 1 With stability being a key point for a study to be conducted correctly, all SAP were reviewed by an independent evaluator (PF), and five cases were excluded for progression.
The stage of the disease was classified according to the GSS2 using the mean of MD and PSD of the four tests. For each patient, all four tests were plotted into GSS2, and cases with borderline stage (ie, two tests falling into different stages) were excluded, a fact that was applicable in nine cases (figure 1).
Statistical analysis
LF was calculated as the mean of the SDs of point-to-point threshold sensitivities in the four repetitions using the following formula:
where i (ranging from 1 to r, which was 54 for 24-2 program and 76 for 30-2 program) identifies the locations of the test, and j (ranging from 1 to n) is the number of tests per patient. LF was then plotted against MD and PSD for each patient, a regression analysis was performed, and a correlation was calculated for the whole dataset. Thereafter, the mean LF, SD and 5% and 95% CIs were calculated for each stage.
The analysis was performed with SPSS (V 13.0; SPSS, Chicago, Illinois). The t test was used for comparisons; p#0.05 was considered significant. Models of linear and second-degree regression were also used to inspect data associations.
RESULTS
The study was conducted on 161 Caucasian patients, whose demographics and perimetric data are given in tables 1 and 2. The populations in the seven sites had similar characteristics (similar age, MD, PSD, LF; p>0.10).
MD was similar in patients with generalised and mixed defects (p¼0.65) and lower in patients with localised defects (p<0.001). PSD was similar in patients with mixed and localised defects (p¼0.39) and lower in patients with generalised defects (p<0.001, table 2).
LF was plotted against MD and PSD. As shown by regression analyses in figures 1 and 2 , the best-fitting curves for these variables were quadratic. LF had a trough of about 1.5 dB at an MD of about +2 dB, progressively increasing to 3 dB, reaching a plateau for MD of about À12/À15 dB and progressively decreasing to 1.5 dB when MD worsened up to À30 dB (y¼À0.0065x 2 À0.1719x+1.9054; R 2 ¼0.30). Similar findings were shown for PSD (figure 3): LF had a trough of 1.5 dB for null PSD; it increased to 3 dB for PSD of 10 dB and progressively decreased to about 2 dB (y¼À0. Figure 1 Study flow. Grey box, patients excluded from the study. GSS2, Glaucoma Staging System 2. 
DISCUSSION
Many strategies have been developed over the years with the aim of providing an early and accurate diagnosis of functional progression of glaucoma, but this task still remains tricky in a number of cases due to the inability to distinguish true change from fluctuation. This clinical problem is very relevant, as shown in the rigorous settings of a multicentre randomised study such as the Normal Tension Glaucoma Study, on which a false call of progression of more than 50% was found.
12
LF is inborn on a psychophysical test such as perimetry, and it is therefore impossible to get over it even at optimal clinical conditions. Mathematical models to soften the effect of LF and to stabilise a series of visual fields have been recently reported, 13 but the best way to reduce variability is to reduce the clinical sources of the problem. Efforts should focus on adopting ideal testing conditions (calm and comfortable room, mild illumination, use of standard operating procedures) and the same perimetric strategy over time (LF largely varies between perimetric strategies 14 ). Our study aimed at calculating the amount of LF in glaucoma patients with different GSS2 stages, which is, to the best of our knowledge, an unexplored issue. In theory, clinicians using this classification system would find our data helpful to discern early glaucoma progression to fluctuation. An interesting finding in our paper was that borderline patients had an MD similar to that of normal subjects (Stage 0) and LF comparable with stage 1 (table 3), despite a difference of more than 2 dB in MD and of more than 0.5 dB in PSD (table 2) . In other words, high LF values might be used to predict the presence of early disease in borderline cases with normal MD. This finding needs verification by properly designed studies.
Our paper confirmed that the relation between MD and LF is curvilinear and not linear (figure 2). 2 15 LF progressively increased from stage 0 to stage 4, reached a plateau for MD of about À13 dB and then decreased when the glaucoma defect became more diffuse (stage 5 had CI similar to stage 1). This curve resembles the curvilinear relation between MD and PSD described by Pearson et al, 16 because they share at least two common determining factors.
The first factor is the asymmetry of the Bebie curve, which increases as long as the glaucoma defect becomes more localised, and progressively decreases in more advanced stages of the disease, when both hemifields are involved. PSD is a direct measure of the asymmetry of the hill of vision with respect to normal, age-matched fields. As locations on the edge of the defect have a higher variability, 17 when a localised defect enlarges, the edge of the scotoma becomes larger, and LF increases, as shown by several studies. 2 3 5 15 18e20 When the defects involve both hemifields, the edge of the scotomas becomes even larger, and one would therefore expect LF to increase. Actually, based on our data, LF progressively decreases, probably because the effect of the enlargement of the absolute scotoma (which fluctuates less than a relative scotoma 17 ) is prevalent as both hemifields progressively deteriorate.
The second factor is a limitation of perimetry for high MD values. At the 'bottom of the scale,' very deep scotomas may be judged absolute by the perimeter; this is due to insufficient stimulus size and luminance to stimulate the damaged ganglion cells. As a consequence, the corresponding points can fluctuate only above their average sensitivity but not below it (inferior fluctuation is not tested being sensitivity null for the perimeter). Also, for this reason, both LF and PSD become reduced for high MD values.
Caution is required when using our data in the clinical settings. Although our dataset was clinically based (the study was a retrospective analysis of data collected in glaucoma patients undergoing routine visits and visual-field tests every 6 months), a fixed number of tests was chosen. Different LF values would be found if a variable number of tests were considered. Also, we excluded patients with different GSS2 stages at the beginning and the end of the study, although changes in type and stage can occur even in stable patients. The subgroup analysis was of limited relevance due to the small number of cases (n<5) falling in stages 1L, 2G, 3G, 4G, 5L. Our study is not informative on patients with normal tension glaucoma or secondary glaucoma, although GSS2 is useful also to monitor these patients.
A strength of the study was the multicentre design; tests were double-checked to exclude progression and similar intersite demographics, perimetric and variability data were found. In contrast to other studies on perimetric fluctuation, which used computer-simulated dataset or visual fields obtained over a short period of time, in our study routine intervals of time of 6 months were maintained between test repetitions.
In summary, LF is a key-point to ascertain perimetric stability or progression, regardless of the strategy used to analyse visualfield tests. This parameter can be easily calculated for each patient, and it may provide useful information in a number of cases. We suggest that clinicians using GSS2 calculate LF at least in patients with suspect progression, in order to obtain an earlier and more accurate diagnosis. 
